What happened in this Health story?

The FDA has issued draft guidance intended to streamline approval of certain individualized gene therapies, a policy shift praised by rare-disease advocates who had criticized the agency’s review approach for rare-mutation treatments.

What is a key fact in this story? (1)

**FDA** published draft guidance on Tuesday that would streamline approvals of some individualized gene therapies.

What is a key fact in this story? (2)

**Paul Scribner** said the FDA draft was “sort of putting a flag in the ground” and called the issue “important” at a rare disease event on Tuesday.

📎 SkimNews has covered FDA 91+ times · see the file →

FDA Drafts Streamlined Path for Personalized Gene Therapies — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-10-27

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

FDA published draft guidance on Tuesday that would streamline approvals of some individualized gene therapies.
Paul Scribner said the FDA draft was “sort of putting a flag in the ground” and called the issue “important” at a rare disease event on Tuesday.
Rare disease advocates are treating the draft as a win after criticizing the FDA’s approach to individualized treatments.
Gene therapy researchers and companies have been energized by breakthroughs in treatments that alter faulty genes inside a person’s cells; they believe many patients with rare mutations could benefit from such personalized medicines.

Why it matters: For the PKD Foundation and other rare-disease advocates, Tuesday’s draft carries direct policy significance because it sets out a streamlined approval route for some individualized therapies after criticism of the FDA’s approach. The immediate consequence is policy recognition: advocates see a win, while researchers and companies remain energized around medicines tailored to rare mutations.